Abstract: 1-Hydroxyimidazole-5-methanamine derivatives characterized by having a lower alkyl group at positions N, N and 5 of the latter derivatives as well as having various substituents at position 2 of the imidazole ring are disclosed. These derivatives are useful as antihypertensive agents in a mammal. Methods for their preparation, use and pharmaceutical compositions also are disclosed.

Abstract: Compounds of formula I ##STR1## in which R.sup.1 is hydrogen, halogen, nitro, trifluoromethyl, lower alkyl or lower alkoxy; R.sup.2 is hydrogen or lower alkyl; R.sup.3 is hydroxy, 1H-tetrazol-5-yl or COOR.sup.4 wherein R.sup.4 is hydrogen or lower alkyl, and X is O, S, SO or SO.sub.2, are disclosed. The compounds of formula I are useful for treating allergic conditions. Methods for the preparation and use of the compounds are disclosed.

Abstract: Compounds of formula I ##STR1## in which R.sup.1 is hydrogen, halogen, nitro, trifluoromethyl, lower alkyl or lower alkoxy; R.sup.2 is hydrogen or lower alkyl; R.sup.3 is hydroxy, 1H-tetrazol-5-yl or COOR.sup.4 wherein R.sup.4 is hydrogen or lower alkyl, and X is O, S, SO or SO.sub.2, are disclosed. The compounds of formula I are useful for treating allergic conditions. Methods for the preparation and use of the compounds are disclosed.

Abstract: Compounds of formula I ##STR1## in which R.sup.1 is hydrogen, halogen, nitro, trifluoromethyl, lower alkyl or lower alkoxy; R.sup.2 is hydrogen or lower alkyl; R.sup.3 is hydroxy, 1H-tetrazol-5-yl or COOR.sup.4 wherein R.sup.4 is hydrogen or lower alkyl, and X is O, S, SO or SO.sub.2, are disclosed. The compounds of formula I are useful for treating allergic conditions. Methods for the preparation and use of the compounds are disclosed.

Abstract: Compounds of formula 1 ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are the same or different selected from the group consisting of hydrogen, halogen, nitro, trifluoromethyl, lower alkyl and lower alkoxy, or R.sup.1 and R.sup.2, R.sup.2 and R.sup.3, or R.sup.3 and R.sup.4 together form a CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 chain and R.sup.3 and R.sup.4, R.sup.1 and R.sup.4 and R.sup.1 and R.sup.2, respectively, are as defined above, R.sup.5 is hydrogen, lower alkyl or a radical of formula -Alk-OR.sup.6 wherein Alk is an alkylene selected from the group consisting of CR.sup.7 R.sup.8, CR.sup.7 R.sup.8 CR.sup.9 R.sup.10, CR.sup.7 R.sup.8 CR.sup.9 R.sup.10 CR.sup.11 R.sup.12 and CR.sup.7 R.sup.8 CR.sup.9 R.sup.10 CR.sup.11 R.sup.12 CR.sup.13 R.sup.14 wherein each of R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13 and R.sup.14 is hydrogen or lower alkyl and R.sup.6 is hydrogen or lower alkyl; R.sup.15 is hydrogen or lower alkyl; X is O, S, SO or SO.sub.2 ; and Y is O or NR.sup.

Abstract: 4H-Pyrano[4,3-d]thiazole derivatives characterized by having a 4H-pyrano[4,3-d]thiazole nucleus having a phenyl substituent at position 2 and a substituent at position 4, said substituent incorporating an acidic or basic function therein, are disclosed. The nucleus is further substituted at position 4 with a lower alkyl and may be optionally substituted in the phenyl ring. The foregoing compounds possess anti-inflammatory and antidepressant activity and methods for their preparation and use are described.

Abstract: 1,3-Dihydropyrrolo[4,3,2-de]isoquinoline derivatives characterized by an amino or hydrazino substituent at position 5 are disclosed. Also included are the related 4,6-dihydropyrrolo[4,3,2-de]-s-triazolo[3,4-a]isoquinoline and its 8-methyl derivative. The compounds are antidepressant and antihypertensive agents. Methods for their preparation and use are disclosed.

Abstract: 1,3,4,5-Tetrahydropyrrolo[4,3,2-de]isoquinoline and its N-alkyl derivatives are disclosed. The compounds are antidepressant and antihypertensive agents. Methods for their preparation and use are disclosed.